AyaStocks
13 hours ago
Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage.
Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243471_1.jpg
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243471__bf477173-b44d-457c-bb35-7984f21e1815.jpg
Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States.
"We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach."
Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity.
While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders.
For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit www.adiamed.com or contact ceo@adiamed.com.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
info
SOURCE: Adia Nutrition Inc.
https://www.newsfilecorp.com/release/243471
$ADIA
AyaStocks
1 day ago
Nice article write-up about $ADIA over the weekend >>
Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
Raising the Standard for Stem Cell Therapy – Quality, Safety, Trust.
Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is spearheading a major initiative to establish standardized regulations for umbilical cord stem cell use across the United States. With a focus on quality, safety, and accountability, the company is setting new industry benchmarks that mandate best practices, third-party verification, and homologous applications. These efforts aim to address inconsistencies in stem cell therapies and ensure patient confidence in the emerging field of regenerative medicine.
The Problem: Inconsistent Stem Cell Quality
One of the most pressing issues in the regenerative medicine industry is the lack of standardized quality control. Many clinics provide substandard or even non-viable—so-called "dead"—stem cells without any means for recipients to verify potency or quantity. This inconsistency has eroded trust and prevented patients from fully benefiting from groundbreaking medical advancements.
Adia Med is committed to changing this landscape. "Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."
A Comprehensive Standardization Framework
To ensure every patient receives live, viable stem cells, Adia Med is implementing a robust framework that prioritizes:
1. Homologous Use Standards
Guidelines will be enforced to ensure that stem cells are used in alignment with their natural functions. This approach maximizes safety and efficacy while preventing misuse.
2. Rigorous Quality Control Protocols
Strict procedures for harvesting, processing, and storing stem cells will maintain their therapeutic power. This includes comprehensive donor screening, isolation, and banking methods to uphold the highest standards of care.
3. Third-Party Verification
Every lab offering stem cell products will be required to conduct third-party verification to guarantee a minimum stem cell count and viability for each batch. This will create a transparent, reliable system ensuring patient safety and product integrity.
4. Best Practices Development
By collaborating with stem cell experts, ethicists, and healthcare practitioners, Adia Med will establish industry-wide standards that eliminate variability and improve patient outcomes.
"Doctors should be getting their stem cells from a lab that has a third-party verified, FDA-validated process that guarantees quality," stated Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're pushing to make that the industry baseline with umbilical cord stem cells."
Tackling a Growing Concern
Reports of patients receiving substandard or ineffective stem cells are increasing. Many patients remain unaware that they have received dead cells until they see no results. Adia Med’s verification standards will require all providers to use only live, viable stem cells in guaranteed minimum quantities. The expected benefits include:
Enhanced Patient Safety: Reducing risks associated with poor-quality or improperly used stem cells.
Greater Treatment Consistency: Ensuring reliable results nationwide, regardless of the provider.
Stronger Industry Credibility: Establishing ethical standards to eliminate unregulated and unscrupulous practices.
Federal Collaboration and the Path Forward
To solidify its efforts, Adia Med plans to present its standards to the newly appointed head of the Department of Health and Human Services (DHHS) and the FDA. The company hopes to work closely with federal agencies to align regulatory frameworks and enforce a national standard for umbilical cord stem cell therapies.
"With the leadership of DHHS and the FDA, we can end uncertainty and deliver real benefits to patients across the country," Powalisz emphasized. "By working together, we can ensure that the potential of regenerative medicine is fully realized."
Adia Med is also calling on regulators, medical professionals, and patient advocates to participate in shaping this national framework. Interested parties can learn more and contribute by visiting www.adiamed.com.
CEO Larry Powalisz and ADIA Nutrition’s Growth Vision
Larry Powalisz, CEO of Adia Nutrition, has been at the forefront of innovation in both the supplement and medical sectors. Under his leadership, Adia Nutrition has expanded its focus beyond dietary supplements to include groundbreaking regenerative medicine solutions.
A significant goal for Powalisz and Adia Nutrition is the company's planned uplisting to the OTCQB market. This move would increase transparency, attract institutional investors, and provide greater credibility within the financial markets. "We are working diligently to meet the requirements for an OTCQB uplisting, which will allow us to reach a broader investor base and enhance shareholder value," Powalisz stated.
The planned uplisting aligns with Adia Nutrition’s long-term vision of becoming a leader in both stem cell therapies and holistic health solutions. By securing a stronger market presence, the company aims to accelerate the adoption of its innovative stem cell initiatives while expanding its reach in the healthcare industry.
Conclusion
Adia Med is leading a transformative effort to standardize umbilical cord stem cell use across the United States. With a focus on quality control, third-party verification, and federal collaboration, the company is setting a new benchmark for the regenerative medicine industry. CEO Larry Powalisz remains committed to pushing for these changes while also positioning Adia Nutrition for future growth through its planned OTCQB uplisting.
As Adia Med prepares to present its framework to DHHS and the FDA, the company stands at the forefront of an industry revolution that promises to improve patient outcomes and restore trust in stem cell therapies. Those interested in joining this movement can find further details at www.adiamed.com.
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks
BCNstocks
2 days ago
Adia Med ($ADIA) is working towards a future where national standards govern the use of stem cell therapies. These standards aim to eliminate variability in treatment quality and establish a system of accountability and transparency.
With a focus on third-party verification, donor screening, and strict quality control measures, Adia Med is ensuring that stem cell treatments are both effective and safe for patients. The company’s efforts are expected to improve patient outcomes, restore confidence in the industry, and help push regenerative medicine toward mainstream acceptance.
By aligning with federal regulatory agencies like the FDA and DHHS, Adia Med hopes to ensure that stem cell therapies are subject to the same rigorous oversight as other medical treatments, leading to a stronger, more reliable industry overall.
Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks
$ADIA #StemCellTherapy
AyaStocks
5 days ago
Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
March 20, 2025 9:30 AM EDT | Source: Adia Nutrition Inc.
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standards to the new head of the Department of Health and Human Services, and the FDA, advocating for federal alignment to address widespread inconsistencies in stem cell therapies.
Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243473_fda.jpg
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243473_fda.jpg
Patients nationwide have long grappled with a troubling issue: many clinics provide low-quality or non-viable—"dead"—stem cells, with no way for recipients to verify potency or quantity. This lack of oversight has eroded trust and limited the promise of regenerative medicine. Adia Med is stepping up to ensure every patient receives live, viable stem cells in the amounts promised, backed by unmatched quality controls.
"Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."
A Robust Standardization Framework
Adia Med's initiative rests on key pillars to fix current shortcomings:
Homologous Use Standards: Guidelines will ensure stem cells are used in line with their natural functions, boosting safety and effectiveness while curbing misuse risks.
Quality Control Protocols: Strict processes for harvesting, processing, and storing stem cells will maintain their therapeutic power, with standards covering donor screening, isolation, and banking.
Third-Party Verification: Every lab nationwide offering stem cell products would be required to provide third-party verification to guarantee a minimum stem cell count and viability for each batch, ensuring a consistent standard of quality, transparency, and reliability across the industry. This auditing ensures transparency and accountability.
Best Practices Development: Collaboration with stem cell experts, ethicists, and practitioners will produce adoptable standards to eliminate variability and enhance patient outcomes.
"Doctors should be getting their stem cells from a lab who has a third-party verified, FDA-validated process which guarantees quality, and we're pushing to make that the industry baseline with umbilical cord stem cells."
"Patients should never have to doubt the viability of their stem cells," said Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're creating a standard where every patient receiving umbilical cord stem cells will receive a certificate from a third party, unequivocally verifying the quantity and viability of their specific batch." This hands-on assurance ensures doctors deliver stem cells from labs with independently verified, FDA-validated processes, setting a new benchmark for quality and boosting patient outcomes across the industry.
Tackling a Pressing Problem
Reports of patients receiving substandard or dead stem cells are rising, often unbeknownst to them. Adia Med's standards, backed by independent verification, will mandate live, viable cells in guaranteed minimum quantities, promising:
Patient Safety: Reduced risks from poor-quality cells or improper use.
Treatment Consistency: Reliable results nationwide, regardless of provider.
Industry Credibility: Ethical standards to eliminate bad actors and restore trust.
Federal Collaboration and Beyond
Adia Med aims to partner with the new head of the Department of Health and Human Services and the FDA, presenting these standards to shape a national framework. "With their leadership, we can end the uncertainty and deliver real benefits," Powalisz added. The company also invites input from regulators, medical professionals, and patient advocates, with participation details forthcoming at www.adiamed.com. Adia invites interested parties to reach out by filling out the contact form at www.adiamed.com.
For inquiries, questions, or further information, you can contact Larry Powalisz at ceo @101Dahlias-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA
$ADIA
AyaStocks
1 week ago
Adia Med to Expand Treatment Offerings with Therapeutic Plasma Exchange (TPE) Across All Future Full Clinic Locations
Winter Park, Florida--(Newsfile Corp. - March 17, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative healthcare solutions, is thrilled to announce that its subsidiary, Adia Med, will ensure that all future full clinic locations across the United States will offer Therapeutic Plasma Exchange (TPE), with its current location already offering this advanced treatment as of today. These full clinics, which will also perform Hematopoietic Stem Cell Transplantation (HSCT) for various conditions using state-of-the-art apheresis machines, will integrate TPE into their offerings, leveraging the same cutting-edge equipment. This forward-thinking expansion will unlock a wide range of applications, including potential benefits for Alzheimer's disease, reinforcing Adia Med's commitment to pioneering patient care.
Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243472_1.jpg
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243472_70824-9959585.jpeg
TPE, a procedure that utilizes an apheresis machine to remove and replace a patient's plasma, will target harmful substances—such as autoantibodies, immune complexes, and toxins—in the bloodstream, offering hope for numerous conditions, including neurodegenerative diseases like Alzheimer's. With all future Adia Med full clinics set to utilize apheresis technology for HSCT, they will seamlessly adopt TPE, maximizing the potential of this sophisticated equipment. The current Adia Med location, now offering TPE, marks the first step in this transformative vision.
"We are excited to announce that all our future full clinics will provide TPE, a treatment with immense potential to change lives, including for those affected by Alzheimer's," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care. As one of just three clinic networks in the U.S. with this technology, we will continue to lead the charge in advanced medical solutions."
Studies have highlighted the promising benefits and versatility of TPE across various conditions, including Alzheimer's disease. A study published in Alzheimer's & Dementia explored the AMBAR trial, which showed that TPE combined with albumin replacement slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer's, suggesting that removing amyloid-beta proteins and other toxic plasma components could play a key role in disease management. Notably, insurance has already covered TPE for Alzheimer's applications in some cases, reflecting growing recognition of its potential.
Additionally, research in Transfusion and Apheresis Science demonstrated TPE's ability to reduce mortality in moderate-to-critical COVID-19 patients, with a risk ratio of 0.41 (95% CI 0.24 to 0.69), underscoring its broader life-saving potential. The American Society for Apheresis (ASFA) also recognizes TPE as a first-line therapy for conditions like Guillain-Barré Syndrome, Myasthenia Gravis, and Thrombotic Thrombocytopenic Purpura (TTP), where it will swiftly remove disease-causing agents to improve outcomes. Future applications may extend to autoimmune disorders, other neurological conditions, and certain drug overdoses, showcasing TPE's extensive therapeutic reach.
The national average cost for TPE ranges from $4,000 to $6,000 per patient, depending on factors like facility fees, the number of sessions required, and regional pricing differences. With Florida's large retiree population—over 4.5 million residents aged 65 and older, many of whom face age-related conditions like Alzheimer's and autoimmune disorders—Adia Med sees a significant market for this treatment. This demographic, combined with the state's growing healthcare infrastructure, positions Florida as an ideal hub for expanding TPE access, addressing a critical need among retirees seeking advanced therapeutic options.
Patients and healthcare providers eager to explore TPE and other services at Adia Med's clinics can visit www.adiamed.com or contact 321-788-0850 for more information as these offerings roll out.
https://www.newsfilecorp.com/release/243472/Adia-Med-to-Expand-Treatment-Offerings-with-Therapeutic-Plasma-Exchange-TPE-Across-All-Future-Full-Clinic-Locations
$ADIA
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
Jaguarjacket
9 hours ago
i_like_bb_stock
13 hours ago
Natural Trader
1 week ago
Hot Features
Premium
